Drug discovery beyond the rule of 5 - Opportunities and challenges

Expert Opinion on Drug Discovery

Volumn 12, Issue 2, 2017, Pages 115-119

  Doak, Bradley C ^a   Kihlberg, Jan ^b  

^a MONASH UNIVERSITY   (Australia)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Beyond rule of 5; conformational flexibility; difficult target; macrocycle; oral absorption

Indexed keywords

CYCLOPEPTIDE; MACROCYCLIC COMPOUND; NONSTRUCTURAL PROTEIN 5A INHIBITOR; DRUG;

BINDING SITE; CELL MEMBRANE PERMEABILITY; CONFORMATION; DRUG SCREENING; EDITORIAL; HYDROGEN BOND; LIPOPHILICITY; PREDICTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SURFACE AREA; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 85003899069     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1264385     Document Type: Editorial

References (20)

1. Surade S, Blundell TL., Structural biology and drug discovery of difficult targets:the limits of ligandability. Chem Biol. 2012;19:42–50. DOI:10.1016/j.chembiol.2011.12.013
2. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23:3–25. DOI:10.1016/S0169-409X(96)00423-1
3. Villar EA, Beglov D, Chennamadhavuni S, et al. How proteins bind macrocycles. Nat Chem Biol. 2014;10:723–732. DOI:10.1038/nchembio.1584•• An innovative analysis of how a representative set of macrocyclic natural products is bound by proteins, including a discussion of how this impacts design of synthetic macrocyclic libraries.
4. Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions:progressing toward the reality. Chem Biol. 2014;21:1102–1114. DOI:10.1016/j.chembiol.2014.09.001•• A clear analysis of different types of protein–protein interactions (PPIs) and the properties of PPI inhibitors that have progressed to clinical trials as well as future opportunities in PPI drug discovery.
5. Doak BC, Zheng J, Dobritzsch D, et al. How beyond rule of 5 drugs and clinical candidates bind to their targets. J Med Chem. 2016;59:2312–2327. DOI:10.1021/acs.jmedchem.5b01286•• An in-depth and comprehensive analysis of drug-target complexes that illustrates the potential of compounds far into bRo5 space to modulate novel and difficult target classes that have large, flat,and groove-shaped binding sites.
6. Doak BC, Over B, Giordanetto F, et al. Oral druggable space beyond the rule of 5:insights from drugs and clinical candidates. Chem Biol. 2014;21:1115–1142. DOI:10.1016/j.chembiol.2014.08.013•• A comprehensive investigation of drugs and clinical candidates with MW >500 Da that reveals significant opportunities for discovery of oral drugs in chemical space beyond the rule of 5, and also defines chemical space that provides a reasonable chance of success.
7. Matsson P, Doak BC, Over B, et al. Cell permeability beyond the rule of 5. Adv Drug Delivery Rev. 2016;101:42–61. DOI:10.1016/j.addr.2016.03.013• A review of how structural features and conformational flexibility affect passive cell permeability, as well as transporter mediated uptake and efflux, obtained by analysis of large sets of bRo5 drugs and clinical candidates, macrocyclic peptides and de novo designed, natural product like macrocycles.
8. Veber DF, Johnson SR, Cheng H-Y, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615–2623.
9. Whitty A, Zhong M, Viarengo L, et al. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discov Today. 2016;21:712–717. DOI:10.1016/j.drudis.2016.02.005•• A clear and educational discussion of the importance of conformational flexibility for good solubility and passive permeability for compounds having MW >600 Da.
10. Fang Z, Song Y, Zhan P, et al. Conformational restriction:an effective tactic in ‘follow-on’-based drug discovery. Future Med Chem. 2014;6:885–901. DOI:10.4155/fmc.14.50
11. Ottiger M, Zerbe O, Güntert P, et al. The NMR solution conformation of unligated human cyclophilin A. J Mol Biol. 1997;272(1):64–81. DOI:10.1006/jmbi.1997.1220
12. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 1996;381(6580):335–341. DOI:10.1038/381335a0
13. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med. 2013;19:202–208. DOI:10.1038/nm.3048
14. Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science. 2010;327:1010–1013. DOI:10.1126/science.1182749
15. Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511:94–98. DOI:10.1038/nature13297
16. Toure M, Cm C. Small-molecule PROTACS:new approaches to protein degradation. Angew Chem Int Ed. 2016;55:1966–1973. DOI:10.1002/anie.201507978
17. Labbé CM, Kuenemann MA, Zarzycka B, et al. iPPI-DB:an online database of modulators of protein–protein interactions. Nucleic Acids Res. 2016;44(D1):D542–D547. DOI:10.1093/nar/gkv982
18. Akke M. Conformational dynamics and thermodynamics of protein–ligand binding studied by NMR relaxation. Biochem Soc Trans. 2012;40:419–423. DOI:10.1042/BST20120094• A discussion of how ligand binding may influence the conformational flexibility of proteins that points out that increased flexibility of the ligand bound target has been found to contribute favorably to the binding affinity.
19. Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem. 2009;16:3903–3917.
20. Driggers EM, Hale SP, Lee J, et al. The exploration of macrocycles for drug discovery–an underexploited structural class. Nat Rev Drug Discovery. 2008;7:608–624. DOI:10.1038/nrd2590• A pioneering and influential paper that points out that macrocycles provide untapped opportunities for discovery of oral drugs directed toward targets having difficult binding sites.